Cox proportional hazards regression models for survival data in cancer research

Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis.

Haematologica·2026

Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sources.

Blood neoplasia·2026

Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR study.

British journal of haematology·2025

Causal effect estimation for competing risk data in randomized trial: adjusting covariates to gain efficiency.

Journal of applied statistics·2025

Cell-free DNA profiles of dermatomyositis and its potential role in discriminating phenotypes.

Frontiers in immunology·2025

Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis.

Blood advances·2025

Clinical Trials and Translational Advances in Metabolic Targeting.

Cancer treatment and research·2026

Tools and Technologies for Studying Cancer Metabolism.

Cancer treatment and research·2026

Cancer and Immune Cells: A Metabolic Battle in the Tumor Microenvironment.

Cancer treatment and research·2026

Biomarkers of Cancer Metabolism and Therapeutic Response.

Cancer treatment and research·2026

Targeting Metabolism in Cancer Therapy: Inhibitors and Approaches.

Cancer treatment and research·2026

Metabolic Reprogramming in Cancer Stem Cells.

Cancer treatment and research·2026

Pre-operative circulating tumour DNA in high-risk primary cutaneous melanoma: prospective feasibility in molecular pathology.

Acta oncologica (Stockholm, Sweden)·2026

Prognostic Associations of BMI and Metabolic Syndrome With Outcomes After Anti-PD-1 Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Immunology·2026

Integrating genetic predictors into subsequent breast cancer risk prediction in survivors of childhood cancer.

Journal of the National Cancer Institute·2026

Real-world treatment landscape and clinical outcomes in first-line advanced or metastatic gastroesophageal adenocarcinoma in the United States.

The oncologist·2026

Integrative multi-omics profiling of insomnia-related molecular features reveals microbiome, immune, and therapy-relevant heterogeneity in colorectal cancer.

Microbiology spectrum·2026

Predicting pancreatic cancer in high-risk individuals and in the general population: how long is the road yet?

Revista espanola de enfermedades digestivas·2026

Related Experiment Videos

Cox proportional hazards regression models for survival data in cancer research

Related Concept Videos

Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis.

Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sources.

Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR study.

Causal effect estimation for competing risk data in randomized trial: adjusting covariates to gain efficiency.

Cell-free DNA profiles of dermatomyositis and its potential role in discriminating phenotypes.

Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis.

Clinical Trials and Translational Advances in Metabolic Targeting.

Tools and Technologies for Studying Cancer Metabolism.

Cancer and Immune Cells: A Metabolic Battle in the Tumor Microenvironment.

Biomarkers of Cancer Metabolism and Therapeutic Response.

Targeting Metabolism in Cancer Therapy: Inhibitors and Approaches.

Metabolic Reprogramming in Cancer Stem Cells.

Pre-operative circulating tumour DNA in high-risk primary cutaneous melanoma: prospective feasibility in molecular pathology.

Prognostic Associations of BMI and Metabolic Syndrome With Outcomes After Anti-PD-1 Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Integrating genetic predictors into subsequent breast cancer risk prediction in survivors of childhood cancer.

Real-world treatment landscape and clinical outcomes in first-line advanced or metastatic gastroesophageal adenocarcinoma in the United States.

Integrative multi-omics profiling of insomnia-related molecular features reveals microbiome, immune, and therapy-relevant heterogeneity in colorectal cancer.

Predicting pancreatic cancer in high-risk individuals and in the general population: how long is the road yet?

Related Experiment Videos

Cox proportional hazards regression models for survival data in cancer research

Related Concept Videos

Related Articles